Other Corporate Information-arkiv

Isofol optimizes the design of its phase Ib/II study following new regulatory approval

GOTHENBURG, Sweden, April 15, 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the German regulatory authority […]

GOTHENBURG, Sweden, March 18, 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the company has expanded

GOTHENBURG, Sweden, 13 March 2026 – Isofol Medical AB (“Isofol” or the “Company”) carried out a rights issue of units

GOTHENBURG, Sweden, 11 March 2026 – Isofol Medical AB (“Isofol” or the “Company”) announces today that the Company has received

GOTHENBURG, Sweden, March 9, 2026 – The Nomination Committee of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) proposes re-election of

GOTHENBURG, Sweden, March 3, 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company will participate

GOTHENBURG, Sweden, February 24, 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today provides an update on the company’s

GOTHENBURG, Sweden, January 9, 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company will participate

GOTHENBURG, Sweden, December 1, 2025 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces that the company will participate in

GOTHENBURG, Sweden, November 13 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the European Patent Office